Announcement on Convening the 2025 Annual Performance Briefing
Filed with SSE · · 3 pages · Chinese
Earlier from BeOne Medicines
- Announcement on Renewing Engagement of Audit Institution for 2026
- BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
- BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
- BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
- ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
Later from BeOne Medicines
- Announcement on Realizing Profitability for the 1st Time and Canceling Stock Abbreviation U
- BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
- Announcement on Signing of Cooperation Agreement and Related Party Transactions
- Announcement on the Record Date for Shareholders' Registration for the 2026 Annual General Meeting
- U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
Follow BeOne Medicines into a list and get an email when it puts out news.
Follow BeOne Medicines